Highlights from ASCO Annual Meeting 2024, Leukemia Edition, Continued

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio's top headlines from the meeting. Andrew Hantel, MD, discusses results of a study on racial disparities in acute myeloid leukemia trials. :27 Christine McMahon, MD,  discusses results of the phase 3 ASC4FIRST study, which examined asciminib versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML. 3:30 Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia treatment in historically marginalized communities. 4:35 Christine McMahon, MD, presents results of a randomized trial of a care model for patients with acute myeloid leukemia and myelodysplastic syndrome. 7:09 Christine McMahon, MD, highlights the ACCESS study into post-transplant graft-versus-host disease, which produced "impressive" rates of post-transplant overall survival at 1 year. 10:22 Read the full coverage here: https://www.healio.com/news/hematology-oncology/20240625/video-a-patients-raceethnicity-affects-eligibility-for-acute-myeloid-leukemia-trials https://www.healio.com/news/hematology-oncology/20240620/video-strong-results-for-asciminib-in-chronic-myelogenous-leukemia https://www.healio.com/news/hematology-oncology/20240625/video-treatment-delays-do-not-lead-to-acute-myeloid-leukemia-survival-disparities https://www.healio.com/news/hematology-oncology/20240620/video-palliative-care-model-increases-quality-of-life-for-patients-with-leukemia https://www.healio.com/news/hematology-oncology/20240620/video-study-produces-impressive-posttransplant-graftversushost-disease-survival-rates Disclosures: Hantel reports no relevant financial disclosures. McMahon reports receiving institutional funding from Syndax and Syros and serving on a safety monitoring committee for Kura Oncology.